Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
BMC Complementary Medicine and Therapies
Published in: BMC Complementary Medicine and Therapies 1/2017

Open Access 01-12-2017 | Research article

The functional property of royal jelly 10-hydroxy-2-decenoic acid as a melanogenesis inhibitor

Authors: Chi-Chung Peng, Hui-Tzu Sun, I-Ping Lin, Ping-Chung Kuo, Jen-Chieh Li

Published in: BMC Complementary Medicine and Therapies | Issue 1/2017

Login to get access

Abstract

Background

It has been reported that royal jelly would reduce melanin synthesis and inhibit the expression of melanogensis related proteins and genes. In this study, we evaluate the anti-melanogenic and depigmenting activity of 10-hydroxy-2-decenoic acid (10-HDA) from royal jelly of Apis mellifera.

Methods

In this study, we assesses the 10-HDA whitening activity in comparison with the changes in the intracellular tyrosinase activity, melanin content and melanin production related protein levles in B16F1 melanoma cells after treating with 10-HDA. Furthermore, the skin whitening effect was evaluated by applying a cream product containing with 0.5%, 1% and 2% of 10-HDA onto the skin of mice (C57BL/6 J) for 3 week to observe the effect of DL*-values.

Results

The results showed that 10-HDA inhibited the MITF protein expression (IC50 0.86 mM) in B16F1 melanoma cells. Western blot analysis revealed that 10-HDA inhibited the activity of tyrosinase and the expression of tyrosinase-related protein 1 (TRP-1), TRP-2, and microphthalmia-associated transcription factor (MITF) in B16F1 melanoma cells. In addition, the 10-HDA was applied on the skin of mice show significantly increased the average skin-whitening index (L value).

Conclusions

The validation data indicated the potential of 10-HDA for use in suppressing skin pigmentation. The 10-HDA is proposed as a candidate to inhibit melanogenesis, thus it could be developed as cosmetics skin care products.
Literature
1.
Chen C, Chen S. Changes in protein components and storage stability of Royal Jelly under various conditions. Food Chem. 1995;54:195–200.CrossRef
2.
Takenaka T. Chemical composition of royal jelly. Honeybee Sci. 1982;3:69–74.
3.
Schmitzova J, Klaudiny J, Albert S, Schroder W, Schreckengost W, Hanes J, Judova J, Simuth J. A family of major royal jelly proteins of the honey bee Apis Mellifera L. Cell Mol Life Sci. 1998;54:1020–30.CrossRefPubMed
4.
Okamoto I, Taniguchi Y, Kunikita T, Kohno K, Iwaki K, Ikeda M. Major royal jelly protein 3 modulates immune responses in vitro and in vivo. Life Sci. 2003;1:2029–45.CrossRef
5.
Fujiwara S, Imai J, Fujiwara M, Yaeshima T, Kawashima T, Kobayashi K. A potent antibacterial protein in royal jelly. J Biol Chem. 1990;265:11333–7.PubMed
6.
Bilikova J, Hanes J, Nordhoff E, Saenger W, Klaudiny J, Simuth J. Apisimin, a new serine-valine-rich peptide from honeybee (Apis Mellifera L.) royal jelly: purification and molecular characterization. FEBS Lett. 2002;528:125–9.CrossRefPubMed
7.
Townsend GF, Brown WH, Felauer EE, Hazlett B. Studies on the in vitro antitumor activity of fatty acids. IV. The esters of acids closely related to 10-hydroxy-2-decenoic acids from royal jelly against transplantable mouse leukemia. Can J Biochem Physiol. 1961;39:1765–70.CrossRefPubMed
8.
Blum MS, Novak AF, Taber S. 10-Hydroxy-2Δ-decenoic acid, an antibiotic found in royal jelly. Sci. 1959;130:452–3.CrossRef
9.
Vucevic D, Melliou E, Vasilijic S, Gasic S, Ivanovski P, Chinou I, Colic M. Fatty acids isolated from royal jelly modulate dendritic cell-mediated immune response in vitro. Int Immunopharmacol. 2007;7:1211–20.CrossRefPubMed
10.
11.
Antinelli JF, Zeggane S, Davico R, Rognone C, Faucon JP, Lizzani L. Evaluation of (E)-10-hydroxydec-enoic acid as a freshness parameter for royal jelly. Food Chem. 2003;80:85–9.CrossRef
12.
Takeshi N, Reiji I. Preparation and the functional properties of water extract and alkaline extract of royal jelly. Food Chem. 2004;84:181–6.CrossRef
13.
Takeshi N, Mizuho S, Rriji I, Hachiro I, Nobutaka S. Antioxidative activities of some commercially honeys, royal jelly, and propolis. Food Chem. 2001;75:237–40.CrossRef
14.
Martos MV, Navajas YR, López JF. Functional Properties of Honey,Propolis, and Royal Jelly. J Food Sci. 2008;73:117–24.CrossRef
15.
Hiroshi I, Masamitsu S, Kazuhiro T, Yoko A, Satoshi M, Hideaki H. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement Altern Med. 2009;9:1–10.CrossRef
16.
Tamura T, Fujii A, Kuboyama N. Antitumor effects of royal jelly (RJ). Nippon Yakurigaku Zasshi. 1987;89:73–80.CrossRefPubMed
17.
18.
Izuta H, Shimazawa M, Tsuruma K, Araki Y, Mishima S, Hara H. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement Altern Med. 2009;6:489–94.
19.
Tseng JM, Huang JR, Huang HC, Tzen JTC, Chou WM, Peng CC. Facilitative production of an antimicrobial peptide-Royalisin and its antibody via an artificial oil body system. Biotechnol Prog. 2011;27:153–61.CrossRefPubMed
20.
Bílikova K, Huang SC, Lin IP, Šimuth J, Peng CC. Structure and antimicrobial activity relationship of royalisin, an antimicrobial peptide from royal jelly of Apis Mellifera. Peptides. 2015;68:190–6.CrossRefPubMed
21.
Okuda H, Kameda K, Morimoto C, Matsuura Y, Chikaki M, Jiang M. Studies on insulin-like substances and inhibitory substances toward angiotensin-converting enzyme in royal jelly. Mitsubachi Kagaku. 1998;19:9–14.
22.
Shinoda M, Nakajin S, Oikawa T, Sato K, Kamogawa A, Akiyama Y. Biochemical studies on vasodilative factor in royal jelly. Yakugaku Zasshi. 1978;98:139–45.CrossRefPubMed
23.
Vittek J. Effect of royal jelly on serum lipids in experimental animals and humans with atherosclerosis. Experientia. 1995;51:927–35.CrossRefPubMed
24.
Ibrahim A, Eldaim MA, Abdel-Daim MM. Nephroprotective effect of bee honey and royal jelly against subchronic cisplatin toxicity in rats. Cytotechnology. 2016;68:1039–48.CrossRefPubMed
25.
Han SM, Yeo JH, Cho YH, Pak SC. Royal Jelly Reduces Melanin Synthesis through Down-Regulation of Tyrosinase expression. Am J Chin Med. 2011;39:1253–60.CrossRefPubMed
26.
Gilchrest BA, Eller MS. DNA photodamage stimulates melanogenesis and other photoprotective responses. J Investig Dermatol Symp Proc. 1999;4:35–40.CrossRefPubMed
27.
28.
Kobayashi T, Vieira WD, Potterf B, Sakai C, Imokawa G, Hearing VJ. Modulation of melanogenic protein expression during the switch from eu- to pheomelanogenesis. J Cell Sci. 1995;108:2301–9.PubMed
29.
Kim SS, Kim MJ, Choi YH, Kim BK, Kim KS, Park KJ, Park SM, Lee NH, Hyun G. Down-regulation of tyrosinase, TRP-1, TRP-2 and MITF expressions by citrus press-cakes in murine B16 F10 melanoma. Asian Pac J Trop Biomed. 2013;3:617–22.CrossRefPubMedPubMedCentral
30.
Land EJ, Ito S, Wakamatsu K, Riley PA. Rate constants for the first two chemical steps of eumelanogenesis. Pigment Cell Res. 2003;16:487–93.CrossRefPubMed
31.
Yen FL, Wang MC, Liang CJ, Ko HH, Lee CW. Melanogenesis inhibitor(s) from Phyla nodiflora extract. Evid Based Complement Alternat Med 2012; ID: 867494. doi: 10.​1155/​2012/​867494.
32.
Tachibana M. MITF: a stream flowing for pigment cells. Pigment Cell Res. 2000;3:230–40.CrossRef
33.
Jung SO, Kim DH, Son JH, Nam KC, Ahn DU, Jo CR. The functional property of egg yolk phosvitin as a melanogenesis inhibitor. Food Chem. 2012;135:993–8.CrossRefPubMed
34.
Yeon HK, Youn OJ, Cho CW, Son DW, Park SJ, Rho JH, Sang YC. Inhibitory effects of Cinnamic acid on melanin biosynthesis in skin. Biol Pharm Bull. 2008;31:946–8.CrossRef
35.
Liu JR, Yang YC, Shi LS, Peng CC. Antioxidant properties of royal jelly associated with larval age and time of harvest. J Agri Food Chem. 2007;56:11447–52.CrossRef
36.
Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium based semiautomated colourimetric assay: assessment of chemosensitivity testing. Cancer Res. 1987;47:936–42.PubMed
37.
Bilodeau ML, Greulich JD, Hullinger RL, Bertolotto C, Ballotti R, Andrisani O. MP-2 stimulates tyrosinase gene expression and melanogenesis in differentiated melanocytes. Pigment Cell Res. 2001;14:328–36.CrossRefPubMed
38.
Martinez-Esparza M, Jimenez-Cervantes D, Solano F, Lonzano JA, JC CB. Mechanism of melanogenesis inhibition by tumor necrosis factor-alpha in B16/F10 mouse melanoma cells. Eur J Biochem. 1998;255:139–46.CrossRefPubMed
39.
Ding HY, Chang TS, Shen HC, Tai SK. Murine tyrosinase inhibitors from Cynanchum Bungei and evaluation of in vitro and in vivo depigmenting activity. Exp Dematology. 2011;20:720–4.CrossRef
40.
Takiwaki H, Serup J. Measurement of color parameters of psoriatic plaques by narrow-band reflectance spectrophotometry and tristimulus colorimetry. Skin Pharmacol. 1994;7:145–50.CrossRefPubMed
41.
Montgomery DC. Experiments with a single factor: The analysis of variance. In Design and Analysis of Experiments. Montgomery, D. C., Eds., John Wiley and Sons, New York, 1991; 75–77.
42.
Park HY, Wu C, Yonemoto L, Murphy-Smith M, Wu H, Stachur CM. MITF-mediates cAMP-induced protein kinase C-b expression in human melanocytes. Biochem J. 2006;395:571–8.CrossRefPubMedPubMedCentral
43.
Goding CR. Mitf from neural crest to melanoma: signal transduction and transcription in the melanocyte lineage. Genes Dev. 2000;14:1712–28.PubMed
44.
Kim DS, Park SH, Kwon SB, Li K, Youn SW, Park KC. (−)-Epigallocatechin-3-gallate and hinokitiol reduce melanin synthesis via decreased MITF production. Arch Pharm Res. 2004;27:334–9.CrossRefPubMed
45.
Choi YK, RhoYK, Yoo KH, Lim YY, Li K, Kim BJ. Effects of vitamin C vs multivitamin on melanogenesis: Comparative study in vitro and in vivo. Intern J Dermatol. 2011;49:218–26.CrossRef
46.
Dynek JN, Chan SM, Liu J, Zha J, Fairbrother WJ, Vucic D. Microphthalmia-associated transcription factor is a critical transcriptional regulator of melanoma inhibitor of apoptosis in melanomas. Cancer Res. 2008;68:3124–32.CrossRefPubMed
47.
Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, Pinkel D, Bastian BC. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135–47.CrossRefPubMed
48.
Chan SH, Lim WK, Scott T Michalski ST, Lim JQ, NDB, Met-Domestici M, Young CNC, Vikstrom K, Esplin ED, Fulbright J, Ang MK, Wee J, Sittampalam K, Farid M, Lincoln SE, Itahana K, Abdullah S, The BT, Ngeow J. Germline hemizygous deletion of CDKN2A–CDKN2B locus in a patient presenting with Li–Fraumeni syndrome. npj Genomic Medicine. 2016; doi:10.​1038/​npjgenmed.​2016.​15
49.
50.
Antonescu CR, Busam KJ, Francone TD, Wong GC, Guo T, Agaram NP, Besmer P, Jungbluth A, Gimbel M, Chen CT, Veach D, Clarkson BD, Paty PB, Weiser MR. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer. 2007;121:257–64.CrossRefPubMed
51.
Abdel-Daim M, Funasaka Y, Komoto M, Nakagawa Y, Yanagita E, et al. Pharmacogenomics of metabotropic glutamate receptor subtype 1 and in vivo malignant melanoma formation. J Dermatol. 2010;37:635–46.CrossRefPubMed
52.
Ohtani Y, Harada T, Funasaka Y, Nakao K, Takahara C, et al. Metabotropic glutamate receptor subtype-1 is essential for in vivo growth of melanoma. Oncogene. 2008;27:7162–70.CrossRefPubMed
53.
Kim J, Kim Y, Yun H, Park H, Kim SY, Lee KG, Han SM, Cho Y. Royal jelly enhances migration of human dermal fibroblasts and alters the levels of cholesterol and sphinganine in an in vitro wound healing model. Nutr Res Pract. 2010;4:362–8.CrossRefPubMedPubMedCentral
54.
Fujii A, Kobayashi S, Kuboyama N, Furukawa Y, Kaneko Y, Ishihama S, Yamamoto H, Tamura T. Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats. Jpn J Pharmacol. 1990;53:331–7.CrossRefPubMed
55.
Koya-Miyata S, Okamoto I, Ushio S, Iwaki K, Ikeda M, Kurimoto M. Identification of a collagen production-promoting factor from an extract of royal jelly and its possible mechanism. Biosci Biotechnol Biochem. 2004;68:767–73.CrossRefPubMed
Metadata
Title
The functional property of royal jelly 10-hydroxy-2-decenoic acid as a melanogenesis inhibitor
Authors
Chi-Chung Peng
Hui-Tzu Sun
I-Ping Lin
Ping-Chung Kuo
Jen-Chieh Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2017
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-017-1888-8

Other articles of this Issue 1/2017

BMC Complementary Medicine and Therapies 1/2017 Go to the issue

Research article

Evaluation of antimycobacterial, leishmanicidal and antibacterial activity of three medicinal orchids of Arunachal Pradesh, India

Research article

Cutaneous neurogenic inflammation in the sensitized acupoints induced by gastric mucosal injury in rats

Research article

Prevalence and determinants of use of complementary and alternative medicine by hypertensive patients attending primary health care facilities in Kinshasa, Democratic Republic of the Congo: a cross-sectional study

Research article

Evaluation of anti-inflammatory and gastric anti-ulcer activity of Phyllanthus niruri L. (Euphorbiaceae) leaves in experimental rats

Research article

A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: a prospective observational study

Research article

A Randomized controlled trial of the effect of yoga and peer support on glycaemic outcomes in women with type 2 diabetes mellitus: a feasibility study